Vanguard Group’s Acurx Pharmaceuticals ACXP Stock Holding History

Vanguard Group’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$58K	Buy	+23,280	New	+$112K	﹤0.01%	4224
2025 Q3	–	Sell	-7,277	Closed	-$74.4K	–	4346
2025 Q2	$74.4K	Sell	7,277 -19,190	-73%	-$155K	﹤0.01%	4164
2025 Q1	$206K	Hold	26,467	–	–	﹤0.01%	4071
2024 Q4	$431K	Hold	26,467	–	–	﹤0.01%	3978
2024 Q3	$1.01M	Buy	26,467 +1,883	+8%	+$79.7K	﹤0.01%	3773
2024 Q2	$1.11M	Hold	24,584	–	–	﹤0.01%	3759
2024 Q1	$1.2M	Buy	24,584 +4,265	+21%	+$277K	﹤0.01%	3747
2023 Q4	$1.56M	Buy	20,319 +14,257	+235%	+$1.08M	﹤0.01%	3688
2023 Q3	$182K	Buy	6,062 +10	+0.2%	+$383	﹤0.01%	4268
2023 Q2	$321K	Buy	6,052 +1,578	+35%	+$94K	﹤0.01%	4223
2023 Q1	$310K	Buy	+4,474	New	+$326K	﹤0.01%	4240

Other funds holding ACXP

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Vanguard Group's ACXP Position: Q4 2025 in Review

Vanguard Group opened a new position in Acurx Pharmaceuticals (ACXP) in Q4 2025: 23,280 shares worth $58K. The stake represents ﹤0.01% of the portfolio and ranks #4224 among its holdings. This is a return to the name: Vanguard Group previously reported a position in ACXP as recently as Q2 2025.

Vanguard Group first reported a position in ACXP in Q1 2023 and has held it in 11 quarters since. The position peaked at $1.56M in Q4 2023. 18 funds tracked by Wall St. Rank hold ACXP as of Q4 2025.

Vanguard Group held 23,280 shares of Acurx Pharmaceuticals worth $58K as of Q4 2025.
Acurx Pharmaceuticals was a new Vanguard Group position in Q4 2025.
Acurx Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4224 holding.
Vanguard Group first reported a position in Acurx Pharmaceuticals in Q1 2023 and has held it in 11 quarters since.
Vanguard Group's Acurx Pharmaceuticals position peaked at $1.56M in Q4 2023.
18 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.